L 697818

Drug Profile

L 697818

Latest Information Update: 09 Feb 2000

Price : $50

At a glance

  • Originator Merck & Co
  • Class
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 09 Feb 2000 Discontinued-Preclinical for Benign prostatic hyperplasia in USA (Unknown route)
  • 04 Feb 2000 No-Development-Reported for Benign prostatic hyperplasia in USA (Unknown route)
  • 20 Feb 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top